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SUMMARY 
The effect of fluoxetine hydrochloride, a 5-HT uptake inhibitor (60 mg/day PO), in preventing 
weight gain associated with nicotine reduction was investigated in participants in a double-blind, 
placebo-controlled smoking-cessation trial. A lunch of cheese pizza and chocolate bars was offered, 
and caloric intake was monitored. The analysis focused on subjects (placebo: n= 11; fiuoxetine: 
n = 10) who succeeded in reaching cotinine levels of less than 50% of their starting cotinine levels 
(signifying a stringent reduction in nicotine intake) and who participated in pre- and post-nicotine 
reduction lunch sessions 70 days apart. Subjects on placebo gained significantly more weight 
(mean + SEM = +3.3 +0.7 kg) than subjects on fluoxetine (-0.6 + 1.2 kg). In fluoxetine-treated 
subjects, weight gain/loss was strongly correlated with initial body mass index, with higher BMI 
being associated with greater decreases in weight. A trend towards decreased caloric intake in the 
fluoxetine group was observed; the change in total calories at lunch was significantly correlated with 
weight change, an association accounted for principally by change in pizza intake. We conclude that 
fluoxetine treatment effectively prevents the weight gain that accompanies nicotine reduction and 
that this phenomenon is mediated, at least in part, by diminished caloric intake. 
INTRODUCTION 
On average,  cigarette smokers weigh less than comparably aged non-smokers ,  and many 
smokers who quit smoking gain 3 - 5  kg in the year following cessation (Pomerleau et  al. ,  1978; 
Grunberg, 1986a; Klesges et  al . ,  1989). Animal studies have established an inverse dose- 
response relationship between nicotine, chronically administered over a period of months, and 
body weight (Bowen et al . ,  1986; Grunberg, 1986b). Though conflicting results have been 
reported (e.g., Hughes et  al.,  in press), research on nicotine replacement tends to corroborate 
these findings: Subjects who quit smoking have been reported to gain less weight when they 
consistently used nicotine polacrilex (Fagerstrom, 1987; Killen et  al. ,  1990), a phenomenon 
that is inversely related to dosage (Stitzer & Gross, 1988). Weight gain is seen not only in 
those who abstain completely, but also in smokers who substantially reduce cigarette consump- 
tion (Perkins et  al.,  1987). 
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The extent to which post-cessation weight gain is related to changes in appetite, specific 
taste preferences, and/or actual food intake, as opposed to changes in basal metabolism or 
activity level, remains unclear. Some studies have suggested that nicotine administration 
reduces food intake (McNair & Bryson, 1983), with a selective effect on sweet-tasting foods 
(Grunberg, 1982; Hall et  al . ,  1989) as well as on taste hedonics (Perkins et  al . ,  1990b); nicotine 
withdrawal has been shown to enhance caloric intake (Hatsukami et  al . ,  1984; Stamford et  al. ,  
1986) and intake of sweets (Perkins e t  a l . ,  1990a). Other studies, however, have failed to 
reveal any effects of nicotine on food intake in rats (Wellman e t  al . ,  1986); human studies also 
have identified no differences in food intake between smokers and nonsmokers (Albanes et  al . ,  
1987) and no increases in caloric intake following withdrawal (Rodin, 1987). Likewise, 
Gilbert and Pope (1982) did not observe any shift in preference for sweet foods following with- 
drawal. There is even evidence in the animal literature to suggest that chronic nicotine 
exposure enhances appetite for sucrose (Jias & Ellison, 1990). 
Fluoxetine (Prozac®), a selective serotonin uptake inhibitor, also has been reported to 
decrease eating and to produce weight loss reliably in controlled clinical trials (Levine et  al. ,  
1987); these effects have been linked to a reduction in "carbohydrate craving" (Ferguson & 
Feighner, 1987), though not specifically to sweet-tasting carbohydrates. Accordingly, the 
present investigation took advantage of a placebo-controlled clinical trial of fluoxetine as an 
adjunct to behavioral smoking cessation treatment to examine the question of how fluoxetine 
might affect weight and intake of foods in the context of decreased nicotine intake. The study 
involved offering the participants a lunch, in a controlled laboratory setting, of two commonly 
eaten high-carbohydrate foods, one sweet-tasting (chocolate) and one not (cheese pizza), on 
five different occasions. We hypothesized that (1) fluoxetine would prevent the weight gain 
commonly seen in smokers who cut down or eliminate nicotine intake, and that (2) subjects on 
fluoxetine would decrease food intake compared to subjects on placebo. We also were inter- 
ested in determining whether the intake of a sweet-tasting food, chocolate, would be differen- 
tially affected. 
SUBJECTS AND METHODS 
Subjects 
Subjects were smokers recruited from the local community to participate in a randomized, placebo-con- 
lxolled, double-blind clinical trial of fluoxetine as an aid to smoking cessation. Subjects were required by the 
sponsor's protocol to be at least 18 years of age, to have a history of smoking 20 or more cigarettes per day for 
at least a year, to have an educational level sufficient to permit intelligent communication with study personnel, 
and to be willing to quit smoking by a stated time in the study. Exclusion criteria were previous participation in 
any fluoxetine study; pregnant or lactating women, and women of childbearing age not using a medically 
accepted means of contraception; regular use of psychotropic drugs or smoking cessation medications; regular 
or intermittent use of smokeless tobacco; history of bipolar depression; or any condition judged to be medically 
unstable. 
Fifty smokers, 30 female and 20 male, were originally enrolled in the trial. Thirty-seven remained in the 
study at the time the current data were collected. Two fluoxetine subjects had withdrawn because of drug side 
effects (allergic reaction/rash; severe fatigue), and a third fluoxetine subject was eliminated because of a 
protocol violation (he tried to halve his dosage because of an anxiety reaction attributed to the drug). One 
placebo subject had been eliminated because she had become pregnant. The nine remaining dropouts all cited 
schedule conflicts or stress as their reasons for withdrawal. Compliance with drug-administration procedure 
was monitored by requiring patients to turn in their empty bottles before new supplies were issued and was 
confirmed subsequently by assays of serum fluoxetine. 
Since the focus of interest in the present study was upon the effects of fluoxetine in the context of nicotine 
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withdrawal rather than upon treatment outcome, we restricted our analysis to subjects who succeeded in 
reaching cotinine levels of less than half their baseline levels (indicating a stringent reduction in nicotine 
intake) by the test session at which they were expected to achieve abstinence (Session 4). Data for two subjects 
were deleted from the analysis, because both their baseline and test Session 1 (pre-randomization, pre-reduc- 
tion) cotinine values were below 50 ng/ml. (The nicotine dependence criterion for admission to the study was 
based on number of cigarettes per day rather than on Fagerstrom Tolerance Questionnaire scores or cotinine 
values.) Of the 23 subjects (11 on placebo and 12 on fluoxetine) who met the criterion for cotinine reduction, 
two were unavailable to participate in the fourth lunch session for reasons unrelated to the study. Thus, 
complete data for the first and fourth sessions were available only for 21 subjects - -  11 on placebo and 10 on 
ftuoxetine. (Seven subjects in each group achieved final cotinine values of 0 ng/ml; cotinine values for the 
remaining subjects ranged from 29 to 138 ng/ml.) Demographic and baseline data for all subjects included in 
this analysis are shown in the Table. 
SUBJECT CHARACTERISTICS (MEAN-I- SEM) 
Placebo Subjects Fluoxetine Subjects 
N 11 10 
% Female  64% 70% 
Age (years) 47.4 + 10.7 43.9 + 10.8 
Baseline Cotinine ( n g / m l )  255.9 + 125.8 250.7 + 105.0 
Final Cotinine (ng / ml) 19.7 + 28.2 22.8 + 45.2 
Fagerstrom TQ (range: 0-11) 6.2 + 1.2 6.0 + 1.4 
C iga re t t e s /Day  27.5 ± 4.8 30.0 ± 1.4 
Baseline Weight  (kg) 75.2 ± 16.6 67.3 ± 11.7 
Height  (m) 1.66 ± 0.1 1.64 + 0.1 
Baseline Body Mass Index (BMI) 27.2 ± 5.3 25.1 ± 3.5 
(weight  + height  2) 
Procedure 
Subjects were exposed, in groups of approximately 10 individuals, to a minimal behavioral intervention for 
smoking. The treatment manual, "Freedom from Smoking" (American Lung Association, 1980), was used. 
Only cursory advice on exercise and dieting was offered. Weight was measured at each treatment visit. Groups 
met from 1000h to 1130h; eating test Sessions 1-5 immediately followed selected treatment visits and were 
carried out, respectively, on Days 7 (the day before randomization to fluoxetine, 60 mg/day PO, or placebo), 21, 
35, 77, and 161. (These numbers represent target dates; for some subjects, actual session dates varied from a 
day to a week.) On the day of the second test session, subjects were instructed to cut down smoking, and on the 
day of the third test session, they were instructed to quit smoking altogether. Thus, by the time of the fourth 
eating test session (10 weeks post-randomization), subjects were expected to have reached a point of  stable 
abstinence while maintaining drug administration; the same conditions were in effect at the fifth eating test 
session. 
During each eating test, subjects were offered a standard lunch consisting of a small cheese pizza (approxi- 
mately 800 g), a large Cadbury's chocolate bar (either 149 g or 207 g) broken into bite-sized squares, and cold 
water. Nutrient content for 1 g of pizza was estimated to be 0.33 g carbohydrate, 0.07 g fat, 0.12 g protein, and 
0.46 g water, with a total of 2.43 kcal; for 1 g chocolate (according to data provided by the manufacturer), 
0.61 g carbohydrate, 0.29 fat, 0.08 g protein, and 0.01 water with a total of 5.39 kcal (Pennington, 1989). 
Subjects ate in groups of approximately 10, which included a random mix of fluoxetine and placebo subjects, 
and were instructed not to talk to one another during the lunch. The pizza and chocolate bars for each subject 
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were weighed before and after lunch. Instructions for carrying out eating test session sequences were taped to 
ensure standardization, and "mood music" was played when instructions were not being presented. No restric- 
tions were placed on the time allocated for eating. Before and after lunch, subjects were given visual analogue 
scales to assess anticipation of and satisfaction derived from eating. After lunch, subjects also were queried 
about possible nausea during lunch and whether they were restricting eating for purposes of weight reduction. 
Subjects were permitted to read magazines upon completing the meal but were not dismissed until several 
minutes after the last subject had completed the last questionnaire, in order to prevent time considerations from 
influencing eating behavior. 
Data analysis 
Because of further subject attrition by Session 5, because of missing lunch data in Sessions 2 and 3, and 
because the inevitable variability of nicotine/cotinine levels during the cutting-down stage would further com- 
plicate interpretation, a decision was made to analyze only the data from the first and fourth eating test sessions. 
Analyses included independent t-tests on change scores between the first and fourth test sessions and correla- 
tions between change in weight and change in food intake. In instances in which directional hypotheses were 
specified, one-tailed statistical tests were used. 
RESULTS 
The 21 subjects included in the analysis did not differ significantly, by two-tailed indepen- 
dent t-tests, from the 29 other subjects who originally enrolled in the trial with respect to any of 
the following baseline variables: age, weight, height, body mass index ( B M I = w e i g h t  + 
height2), total Fagerstrom TQ score, or gender composition. Likewise, no significant differ- 
ences in food intake at the first eating session were detected. 
The groups did not differ significantly, by two-tailed independent t-tests, on any of the 
baseline characteristics shown in the Table. Most subjects were of normal weight, though four 
(three on placebo and one on fluoxetine) had a BMI in excess of 30, categorizing them as over- 
weight. No significant differences in nausea or restrictive eating were detected between the two 
groups for either test session. Changes in anticipation of eating and of postprandial satisfaction 
between the two test sessions did not differ significantly between the two groups. Although 
subjects were blinded to their drug status, 8 of the 11 placebo subjects and 7 of  the 10 
fluoxetine subjects were able to guess correctly at the time of the second test session. (Except 
for one fluoxetine subject who thought she was on placebo, the remainder said they did not 
know.) No feedback was given regarding the correctness of  subjects'  guesses about which 
study drug they were taking; indeed, none 
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NICOTINE REDUCTION, FLUOXETINE, AND WEIGHT GAIN 437 
3.3 +0.7 kg and the fluoxetine group showing a decrease of 0.6 + 1.2 kg (t [19] = 3.02, p=O.O00, 
one-tailed). 
In an attempt to determine the extent to which observed changes in weight were related to 
initial weight status, change in weight was related to BMI separately for the two groups. In the 
fluoxetine group, baseline BMI was strongly negatively correlated with weight change (r =-.95, 
p =0.000, two-tailed), higher BMI being associated with greater weight loss. Weight change in 
the placebo group was positively, but not significantly, correlated with baseline BMI (r = +.23, 
p = NS, two-tailed). 
With regard to changes in total calories consumed at lunch between the fourth session and 
the first session, subjects in the fluoxetine group showed a trend (t[19] = 1.39, p=0.089, one- 
tailed) towards reduced consumption (-181 kcal) compared to subjects on placebo (+ 10 kcal). 
The fluoxetine group consumed 172 fewer kcal of pizza and 9 fewer kcal of chocolate, whereas 
the placebo group consumed 48 fewer kcal of pizza but 58 more kcal of chocolate. Changes in 
intake of the individual foods did not differ significantly, nor did changes in the ratio of choco- 
late to pizza caloric intake. 
In order to investigate further the question of whether the observed weight changes might be 
related to changes in food intake, correlations between weight change and change in intake 
were computed for the entire sample of 21 subjects, comparing Session 4 with Session 1. 
Change in total lunch calories were significantly correlated with weight change (r = +.44, 
p = 0.048, two-tailed); this association was principally accounted for by changes in intake of 
pizza (r = +.49, p = 0.026, two-tailed); no correlation was detected for change in chocolate 
intake (r = +.09, p = NS, two-tailed). 
DISCUSSION 
There were no baseline differences between the entire sample and the subjects eliminated 
from the analyses. Likewise, no differences were detected between the two groups. 
Subjects showed clear-cut differences in weight-change profiles over the 10 weeks that 
elapsed between eating test Sessions 1 and 4, with fluoxetine-treated subjects exhibiting a slight 
decline and placebo-treated subjects gaining more than 3 kg. The weight gain for the placebo 
subjects is in keeping with the magnitude of changes reported after stringent nicotine reduction 
(Klesges et al., 1989). 
Over the same interval, lunch food intake showed a trend toward diminished consumption, 
particularly in pizza. Changes in eating showed a significant positive correlation with changes 
in weight in individual subjects, suggesting that prevention of weight gain by fluoxetine may 
have been related, at least in part, to decreased food consumption. Our correlation of +.44 is 
strikingly similar to the correlation of +.41 reported by Spring et al. (1991) between weight 
change and caloric intake, examined under somewhat more naturalistic conditions in a 
combined sample of obese female subjects who stopped or drastically reduced smoking while 
being treated with placebo or another serotonergic compound, d-fenfluramine (a 5-HT releaser 
and uptake inhibitor). Neither our study nor that of Spring et al., however, rules out the possi- 
bility of additional fluoxetine effects on basal metabolism or physical activity. Blundell (1986), 
in a review of serotonin manipulations on the structure of eating behavior, pointed out that 
enhancement of serotonin neurotransmission typically results in a reduction in meal size and a 
curtailment of eating rate, consistent with the entrainment of satiety. The present findings, 
based on total caloric intake of a standardized lunch, are in keeping with the observation of 
decreased meal size; unfortunately, eating rate was not monitored, so the impact of fluoxetine 
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on this variable cannot be ascertained. The lack of significant differences between the 
fluoxetine and placebo groups in either anticipation of eating or satisfaction from the meal fails 
to support the possibility that fluoxetine affects awareness of hunger or satiety; a larger sample 
and a different design would be required to settle this issue definitively. 
The present study does not resolve the question of whether fluoxetine differentially affected 
intake of sweet-tasting food (Spring et al.,  1987). Placebo-treated subjects consumed more 
chocolate in Session 4 than in Session 1, but the order in which the foods were consumed was 
neither controlled nor monitored, and the nutrient composition between the two foods varied in 
other respects as well (e.g., fat content). The main findings of reduced caloric intake and pre- 
vention of weight gain in subjects taking fluoxetine, however, are consistent with previous 
reports of decreased appetite and weight loss in overweight nonsmokers treated with fluoxetine 
(Ferguson & Feighner, 1987; Levine et  al.,  1987). They also are supported by the findings of 
Spring et al. (1991), who observed that placebo-treated subjects increased carbohydrate intake 
and gained weight, whereas d-fenfluramine-treated subjects returned quickly to baseline carbo- 
hydrate intake levels and lost weight. Our results, however, will need to be replicated in larger 
samples, with presentation of a larger variety of food choices, systematic variation of nicotine 
and fluoxetine dosing, and more rigorous control over such experimental and subject variables 
as fasting status, caffeine intake, and baseline weight. Differences in other factors that might 
have affected eating behavior, such as nausea and restrictive eating, were not observed in our 
small sample but cannot be ruled out altogether. Of particular importance are understanding the 
effects of fluoxetine on sweet taste preference and metabolism in both normal-weight and obese 
individuals, as well as obtaining a better definition of actual eating behavior over a larger 
sampling interval. 
Some investigators have held that fear of weight gain may serve as a motive for continued 
smoking (Shor et al., 1981; Sorensen & Pechacek, 1987) and that concem about weight gain 
deters some smokers from attempting to quit (Klesges & Klesges, 1988). Certainly, for those 
smokers who have shown large increases in weight in previous quit attempts or who are 
daunted by the prospect of gaining weight, adjunctive treatment to prevent weight gain may 
diminish some of the unpleasantness of smoking cessation. Different approaches are currently 
available for this purpose. For example, formal behavior modification procedures for weight 
control have been added to smoking treatment. There is some evidence, however, that the com- 
bination of two intensive behavioral treatments may not be efficacious and may even be 
counter-productive (Sharon Hall, personal communication). Nicotine polacrilex has been 
reported to help prevent weight gain after quitting cigarettes. In a study by Stitzer and Gross 
(1988), for example, the use of nicotine gum kept the weight gain of the treatment group (+ 1.7 
kg) to little over half that of the placebo group; subjects who made the greatest use of the gum 
(chewing a mean of nine pieces per day) gained the least (+ 0.7 kg). On the other hand, Hughes 
et al. (in press), in a large nicotine gum trial, failed to observe prevention of weight gain; the 
investigators speculated that self-dosing had been inadequate to maintain weight control. Such 
findings raise the question of whether a higher nicotine replacement dosage is needed for 
weight management than for stopping smoking; if so, the implications of using doses of 
nicotine in excess of the minimum required to promote smoking cessation for the sole purpose 
of controlling weight must be carefully reviewed. 
Taking these considerations into account, we conclude that treatment with fluoxetine is as 
efficacious as any technique for preventing post-smoking cessation weight gain that has been 
tried to date and has the advantage that compliance with the procedure/dosing may be more 
readily achieved. The drug may prove especially helpful in countering weight gain pursuant to 
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nicotine withdrawal in obese smokers, as suggested by the strong relationship between BMI  
and weight change in the fluoxetine-treated subjects. Our findings, if corroborated, may serve 
as a prototype for the specific use of  pharmacological techniques to deal selectively with impor- 
tant components in the sequence of  changes and adjustments that go with giving up smoking. 
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